The ROS1 tyrosine kinase inhibitor (TKI) taletrectinib demonstrated high overall and intracranial responses, and a favorable safety profile with low incidence of neurologic adverse events in TKI-naive and TKI-pretreated patients with ROS1+ non-small cell lung cancer (NSCLC).
Taletrectinib shows high response rates and safety in ROS1+ lung cancer patients
- Post author:
- Post published:September 11, 2024
- Post category:uncategorized
- Post comments:0 Comments